GLP-1 drugs like semaglutide were originally developed for diabetes and weight management, but recent trials show they also lower cardiovascular risk. The SELECT trial found that semaglutide reduced major cardiac events in adults with existing heart disease and obesity, even without diabetes. If you have risk factors for heart disease, talking with a cardiologist about GLP-1 therapy may be worth considering.
You have probably heard about GLP-1 drugs through weight loss headlines. What gets less attention is what these medications mean for your heart. If you live with obesity, type 2 diabetes, or a history of heart trouble, this distinction matters. Semaglutide trials have moved beyond blood sugar control and weight numbers to ask a bigger question: can these drugs actually protect your heart? The answer emerging from recent cardiovascular risk research is encouraging, and it is changing how cardiologists approach prevention for patients who have struggled with limited options before.
What Are GLP-1 Drugs and How Do They Affect the Heart?
GLP-1 drugs, short for glucagon-like peptide-1 receptor agonists, work by mimicking a hormone your body naturally produces after eating. They slow digestion, reduce appetite, and help regulate blood sugar. For years, these effects made GLP-1 drugs a go-to option for managing type 2 diabetes and obesity.
Your heart benefits in ways that go beyond weight loss alone. GLP-1 drugs appear to reduce inflammation, improve blood vessel function, and ease the strain that excess weight and high blood sugar place on your cardiovascular system.
What Semaglutide Trials Reveal About Cardiovascular Risk
Semaglutide trials have given cardiologists some of the clearest evidence yet that treating metabolic conditions can directly protect the heart.
Who Should Consider GLP-1 Drugs for Cardiovascular Risk Reduction?
Not everyone with excess weight needs a GLP-1 drug, and that is an important distinction. These medications are typically considered for adults who have:
- Established heart disease. A history of heart attack, stroke, or peripheral artery disease alongside obesity.
- Type 2 diabetes with added risk factors. High blood pressure, high cholesterol, or a family history of heart disease.
- Obesity without diabetes. Based on SELECT trial findings, benefits may extend to patients without a diabetes diagnosis.
Choose GLP-1 therapy if your cardiologist determines your cardiovascular risk outweighs the medication’s potential side effects, which can include nausea and digestive discomfort. This decision should always be made alongside a provider who understands your full health picture, not through a standalone prescription.
When to See a Cardiologist in Brooklyn
You do not need a cardiac event to justify a conversation about prevention. If you live with obesity, diabetes, or a family history of heart disease, an early evaluation gives you more options and a clearer path forward. If you are searching for the best cardiologist in Brooklyn to discuss whether GLP-1 drugs are right for your heart, look for a provider who treats metabolic and cardiovascular health together, the way the SELECT trial findings suggest they should be.
Take the Next Step Toward a Healthier Heart
GLP-1 drugs are reshaping what cardiovascular prevention can look like for patients who once had few options. If you’re experiencing symptoms of a blocked artery or want to learn more about your treatment options, our Cardiology team is here to help. Reach out today by calling +1-718-367-2555 or visiting us at 1797 Pitkin Avenue, Brooklyn, NY 11212 to schedule a consultation and take the next step toward a healthier heart.




